|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.
|
30456845 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.
|
29755126 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
As GIPC proteins are involved in trafficking, signaling and recycling of RTKs, GPCRs, integrins and other transmembrane proteins, dysregulation of GIPCs results in human pathologies, such as cancer and hereditary deafness.
|
23743496 |
2013 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
GIPC1 is highly expressed in a number of human malignancies, including breast, ovarian, gastric, and pancreatic cancers.
|
21209904 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, these findings demonstrate the importance of GIPC in breast tumor progression, which has a potentially significant impact on the development of therapies against many common cancers expressing GIPC, including breast and renal cancer.
|
21047775 |
2010 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Since other proteins, like 5T4, associate with TIP-2/GIPC and are linked with cancer, we explore the possibility that TIP-2/GIPC may be a common factor involved in the cancer process.
|
11798178 |
2002 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
NRP-1 interacts with GIPC1 and SYX to activate p38 MAPK signaling and cancer stem cell survival.
|
30456845 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.
|
29755126 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
As GIPC proteins are involved in trafficking, signaling and recycling of RTKs, GPCRs, integrins and other transmembrane proteins, dysregulation of GIPCs results in human pathologies, such as cancer and hereditary deafness.
|
23743496 |
2013 |
|
Primary malignant neoplasm
|
0.050 |
PosttranslationalModification
|
group |
BEFREE |
Therapeutic implications of GIPC1 silencing in cancer.
|
21209904 |
2010 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Since other proteins, like 5T4, associate with TIP-2/GIPC and are linked with cancer, we explore the possibility that TIP-2/GIPC may be a common factor involved in the cancer process.
|
11798178 |
2002 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of GIPC1 by small interfering RNA (siRNA) significantly reduces the proliferation and invasion of glioma cells in vitro and increases its apoptosis.
|
27481513 |
2016 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
GIPC1 upregulation in breast, ovarian and pancreatic cancers promotes tumor proliferation and invasion, whereas GIPC1 downregulation in cervical cancer with human papillomavirus type 18 infection leads to resistance to cytostatic transforming growth factorβ signaling.
|
23743496 |
2013 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Moreover, we showed that wild-type p53 reduced GIPC-induced breast cancer cell survival, whereas mutant p53 inhibited GIPC-induced cell invasion.
|
21047775 |
2010 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Matrigel invasion assays show that RNAi-mediated depletion of GIPC1 dramatically decreases MDA-MB-231 cell invasion.
|
20634288 |
2010 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Further research is necessary to determine whether targeting knockdown of ADRM1 in 20q13-amplified ovarian cancers results in growth inhibition and tumor suppression via downstream targets GIPC1 and RECK.
|
21432940 |
2011 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Finally, we demonstrated that an N-myristoylated GIPC peptide (CR1023, N-myristoyl-PSQSSSEA) capable of blocking the PDZ domain of GIPC successfully inhibited MDA-MB-231 cell proliferation, survival, and further in vivo tumor growth.
|
21047775 |
2010 |
|
Mammary Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Taken together, these findings demonstrate the importance of GIPC in breast tumor progression, which has a potentially significant impact on the development of therapies against many common cancers expressing GIPC, including breast and renal cancer.
|
21047775 |
2010 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Additionally, a cell-permeable GIPC-PDZ inhibitor was able to block tumor growth significantly without showing toxicity in a mouse model.
|
19509165 |
2009 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
LHGDN |
A human monoclonal autoantibody to breast cancer identifies the PDZ domain containing protein GIPC1 as a novel breast cancer-associated antigen.
|
18721486 |
2008 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Native human autoantibodies targeting GIPC1 identify differential expression in malignant tumors of the breast and ovary.
|
18721484 |
2008 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Studies have shown that GIPC1/Synectin is an essential adaptor protein of receptors that play an important role in cancer progression and therapy resistance.
|
23128896 |
2012 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Moreover, we showed that wild-type p53 reduced GIPC-induced breast cancer cell survival, whereas mutant p53 inhibited GIPC-induced cell invasion.
|
21047775 |
2010 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Although the importance of RGS-GAIP-interacting protein (GIPC) in the biology of malignant cells is well known, the molecular mechanism of GIPC in the inhibition of tumor progression has not been identified.
|
21047775 |
2010 |
|
Pancreatic carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Suppression of GIPC1 in human pancreatic cancer cells inhibits in vivo tumor growth in immunodeficient mice.
|
21209904 |
2010 |